Open Access

14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma

Retraction in: /10.3892/etm.2024.12368

  • Authors:
    • Liang Liu
    • Zhixiong Liu
    • Hao Wang
    • Long Chen
    • Fuqiang Ruan
    • Jihui Zhang
    • Yi Hu
    • Hengshan Luo
    • Shuai Wen
  • View Affiliations

  • Published online on: December 21, 2017     https://doi.org/10.3892/etm.2017.5664
  • Pages: 2381-2387
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioma is a type of tumor that affects the central nervous system. It has been demonstrated that 14‑3‑3β, a protein that is mainly concentrated in the brain, serves an important role in tumor regulation. However, the mechanism of action of 14‑3‑3β that underlies the pathogenesis of glioma remains to be elucidated. In the present study, 14‑3‑3β was silenced by RNA interference in the human glioma cell line U373‑MG. Following knockdown of 14‑3‑3β, the proliferation, colony formation, cell cycle progression, migration and invasion of U373‑MG cells were significantly decreased (P<0.01), whereas cell apoptosis was increased (P<0.01). Furthermore, in a tumor xenograft experiment, silencing 14‑3‑3β significantly inhibited the in vivo tumor growth of U373‑MG cells (P<0.01). The results demonstrated that 14‑3‑3β levels were significantly higher in human glioma tissues compared with normal brain tissues (P<0.01) and high 14‑3‑3β expression was significantly associated with advanced pathological grade (P<0.03) and low Karnofsky performance scale (P<0.003). Patients with glioma who had high 14‑3‑3β levels had a significantly shorter survival time compared with those with low expression of 14‑3‑3β (P=0.031), suggesting that 14‑3‑3β may be an effective predictor of the prognosis of patients with glioma. The results of the present study indicate that 14‑3‑3β serves an oncogenic role in glioma, suggesting that 14‑3‑3β may have potential as a promising therapeutic target for glioma.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu L, Liu Z, Wang H, Chen L, Ruan F, Zhang J, Hu Y, Luo H and Wen S: 14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma Retraction in /10.3892/etm.2024.12368. Exp Ther Med 15: 2381-2387, 2018
APA
Liu, L., Liu, Z., Wang, H., Chen, L., Ruan, F., Zhang, J. ... Wen, S. (2018). 14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma Retraction in /10.3892/etm.2024.12368. Experimental and Therapeutic Medicine, 15, 2381-2387. https://doi.org/10.3892/etm.2017.5664
MLA
Liu, L., Liu, Z., Wang, H., Chen, L., Ruan, F., Zhang, J., Hu, Y., Luo, H., Wen, S."14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma Retraction in /10.3892/etm.2024.12368". Experimental and Therapeutic Medicine 15.3 (2018): 2381-2387.
Chicago
Liu, L., Liu, Z., Wang, H., Chen, L., Ruan, F., Zhang, J., Hu, Y., Luo, H., Wen, S."14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma Retraction in /10.3892/etm.2024.12368". Experimental and Therapeutic Medicine 15, no. 3 (2018): 2381-2387. https://doi.org/10.3892/etm.2017.5664